Department of Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada.
Department of Cardiac Surgery, Montreal Heart Institute, Montreal, Quebec, Canada.
Can J Cardiol. 2021 Jul;37(7):1041-1053. doi: 10.1016/j.cjca.2021.05.001. Epub 2021 May 12.
The management of valvular heart disease has changed dramatically over the past decade with advances in cardiac imaging, the use of novel biomarkers, and the development of transcatheter valve repair and replacement technology. International society guidelines have kept pace to provide recommendations for diagnosis, follow-up, and timing of intervention. The most challenging patient cohort for clinicians are patients with asymptomatic severe disease in whom the optimal timing of intervention can be ill-defined. It is a fine balance between the risks of early intervention on asymptomatic patients and improving patient outcomes by preventing long-term cardiac complications. The key in optimal patient management is gathering the necessary information on patient risk and combining that with the risk, efficacy, and durability of valve interventions to arrive at the appropriate timing for intervention. This group of patients will be the focus of this review as we delve into the natural history, recommended follow-up, and indications for intervention in patients with degenerative aortic and mitral valve disease.
在过去的十年中,随着心脏成像技术的进步、新型生物标志物的应用以及经导管瓣膜修复和置换技术的发展,瓣膜性心脏病的治疗发生了巨大变化。国际社会指南也与时俱进,为诊断、随访和干预时机提供了建议。对于临床医生来说,最具挑战性的患者群体是无症状严重疾病患者,他们的干预时机可能难以确定。在无症状患者早期干预的风险和通过预防长期心脏并发症改善患者结局之间存在着微妙的平衡。在最佳患者管理中,关键是收集有关患者风险的必要信息,并将其与瓣膜干预的风险、疗效和耐久性相结合,以确定干预的适当时机。这组患者将是本文的重点,我们将深入探讨退行性主动脉瓣和二尖瓣疾病患者的自然史、推荐的随访和干预指征。